

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO <h2 style="margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="margin: 0; font-style: italic;">(Use as many sheets as necessary)</p>				<h3 style="margin: 0;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">To be assigned</td> </tr> <tr> <td>Filing Date</td> <td>October 16, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>G. KUKOLJ, et al</td> </tr> <tr> <td>Art Unit</td> <td>To be assigned</td> </tr> <tr> <td>Examiner Name</td> <td>To be assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>13/083-2-C1</td> </tr> </table>		Application Number	To be assigned	Filing Date	October 16, 2003	First Named Inventor	G. KUKOLJ, et al	Art Unit	To be assigned	Examiner Name	To be assigned	Attorney Docket Number	13/083-2-C1
Application Number	To be assigned																
Filing Date	October 16, 2003																
First Named Inventor	G. KUKOLJ, et al																
Art Unit	To be assigned																
Examiner Name	To be assigned																
Attorney Docket Number	13/083-2-C1																
Sheet	1	of	5														

[illegible]

class/
subclass

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ² Number ³ Kind Code ⁴ (if known)			
BC		WO 98/04008	01-29-1998	Motorola Inc.	
		WO 98/39031	9-11-1998	Washington University	
		WO 00/66623	11-9-2000	Boehringer Ingelheim	
		WO 01/89364	11-29-2001	Washington University	

Examiner Signature	<i>Berglund</i>	Date Considered	<i>05/10/2005</i>
-----------------------	-----------------	--------------------	-------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

Complete If Known

Application Number

To be assigned

Filing Date

October 16, 2003

First Named Inventor

G. KUKOLJ, et al

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

13/083-2-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BLi		FOURNIER, SUREAU et al.; In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus; J. Virol.; 1998, V. 79; 2367-2374	
		GRAKOU, WYCHOWSKI et al.; Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products; J. Virol.; 1993, V. 67, No. 3; 1385-1395	
		HIJIKATA, MIZUSHIMA et al.; Two Distinct Proteinase Activities Required for the Processing of a Putative Nonstructural Precursor Protein of Hepatitis C Virus; J. Virol.; 1993, V. 67, No. 8; 4665-4675	
		BARTENSCHLAGER, AHLBORN-LAAKE et al.; Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions; J. Virol.; 1993, V. 67, No. 7; 3835-3844	
		REED, XU et al.; Phosphorylation of the Hepatitis C Virus NS5A Protein In Vitro and In Vivo: Properties of the NS5A-Associated Kinase; J. Virol.; 1997, V. 71, No. 10; 7187-7197	
		KHROMYKH, WESTAWAY; Subgenomic Replicons of the Flavivirus Kunjin: Construction and Applications; J. Virol.; 1997, V. 71, No. 2; 1497-1505	
		BEHRENS, GRASSMANN et al.; Characterization of an Autonomous Subgenomic Pestivirus RNA Replicon; J. Virol.; 1998, V. 72, No. 3; 2364-2372	
		MIZUTANI, KATO et al.; Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2; J. Virol.; 1996, V. 70, No. 10; 7219-7223	
		MOSER, TRATSCHIN et al.; A Recombinant Classical Swine Fever Virus Stably Expresses a Marker Gene; J. Virol.; 1998, V. 72, No. 6; 5318-5322	
		KEDA, SUGIYAMA et al.; Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus; Virus Research; 1998, V. 56; 157-167	

Examiner
Signature

Reagon L:

Date
Considered

05/16/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	To be assigned
				Filing Date	October 16, 2003
				First Named Inventor	G. KUKOLJ, et al
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	5	Attorney Docket Number	13/083-2-C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BL ✓ ✓ ✓		DASH, HALIM et al.; Transfection of HepG2 Cells with Infectious Hepatitis C Virus Genome; Amer. J. Pathology; 1997, V. 151; 363-373	
		KWONG, KIM et al.; Hepatitis C Virus NS3/4A protease; Antiviral Research 1998, V. 40; 1-18	
		LANFORD, SUREAU et al; Demonstration of in Vitro Infection of Chimpanzee Hepatocytes with hepatitis C Virus Using Strand-Specific RT/PCR; Virology; 1994, V. 202; 606-614	
		LESBURG, CABLE et al; Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site; Nat. Struc. Biolo; 1999 V.6 No. 10; 937-943	
		LOHMANN, KORNER et al; Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line; Science; 1999, V.285; 110-113	
		LOHMANN, KORNER et al; Mutations in Hepatitis C virus RNAs Confering Cell Culture Adaptation; J. Virology; 2001, V. 75, No. 3, 1437-1449	
		LOVE, PARGE et al; The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site; Cell; 1996, V. 87, 331-342	
		SHIMIZU, Purcell et al; Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro; Proc. Natl. Acad. Sci. USA; 1993, V. 90; 6037-6041	
		YANAGI, ST. CLAIRE et al; In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone; Proc. Natl. Acad. Sci. USA 1999, V. 96, 2291-2295	

Examiner Signature	<i>Boogers L.</i>	Date Considered	05/10/2005
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	To be assigned	
			Filing Date	October 16, 2003	
			First Named Inventor	G. KUKOLJ, et al	
			Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	4	of	5	Attorney Docket Number	13/083-2-C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BLI ↓		BRESSANELLI, TOMEI et al.; Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus; PNAS; 1999, V. 96, No. 23; 13034-13039	
		KIM, MORGENSTERN et al.; Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding; Structure; 1998, V. 6; 89-100	
		YAN, LI et al.; Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus; A 2.2 Å resolution structure in a hexagonal crystal form; Protein Science; 1998, V. 7; 837-847	
		YAO, HESSON et al.; Structure of the hepatitis C virus RNA helicase domain; Nature Structural Biology; 1997, V. 4, No. 6; 463-467	
		ITO, MUKAIGAWA et al.; Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus; J. Gen. Virol.; 1996, V. 77; 1043-1054	
		YOO, SELBY et al.; Transfection of a Differentiated Human Hepatoma Cell Line (Huh7) with In Vitro-Transcribed Hepatitis C Virus (HCV) RNA and Establishment of a Long-Term Culture Persistently Infected with HCV; J. Virol.; 1992, V. 69, No. 1; 32-38	
		AGO, ADACHI et al.; Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus; Structure; 1999, V. 7; 1417-1426	
		BLIGHT, KOLYKHALOV et al.; Efficient Initiation of HCV RNA Replication in Cell Culture; Science; 2000, V. 290; 1972-1974	

Examiner Signature	<i>Basquini</i>	Date Considered	05/10/2005
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	To be assigned	
			Filing Date	October 16, 2003	
			First Named Inventor	G. KUKOLJ, et al	
			Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	5	of	5	Attorney Docket Number	13/083-2-C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BL:		CHO, HA et al.; Crystal Structure of RNA Helicase from Genotype 1b Hepatitis C Virus; J. Biol. Chemistry; 1998, V. 273, No. 24; 15054-15052	
		GALE JR., KORTH et al.; Evidence that Hepatitis C Virus Resistance to Interferon is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein; Virology; 1997, V. 230; 217-227	
		GRAKOU, MCCOURT et al.; A second hepatitis C virus-encoded proteinase; Proc. Natl. Acad. Sci. USA; 1993, V. 90; 10583-10587	
		GOU, JU-TAO et al.; Effect of Alpha Interferon on the Hepatitis C virus Replicon; J. Virol.; 2001, 75(18):8516-8523	
		HIJIKATA, MAKOTO et al.; Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis; Proc. Natl. Acad. Sci.; 1991, 88:5547-5551	
		KIM, DONG WOOK et al.; C-Terminal Domain of the Hepatitis C Virus NS3 Protein Contains an RNA Helicase Activity; 1995, 215(1):160-166	
		KIM, J.-E. et al; Subcellular localization of hepatitis C viral proteins in mammalian cells; Arch Virol.; 1999, 144:329-343	
		KIM, J.L. et al; Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide; Cell; 1996, 87:343-355	
		KRIEGER, NICOLE, et al; Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations; J. of Virol.; 2001, 75(10):4614-4624	
		International Search Report issued March 3, 2003 for PCT/CAD1/01843 the counterpart of Parent U.S. Application 10/029,907.	

Examiner Signature	<i>Benjamin</i>	Date Considered	05/10/2005
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.